iiinova — where your digital self keeps evolving

Foresight Diagnostics @foresight-dx.bsky.social · 17/12/2025

A few days ago, Foresight had our annual holiday party, where we celebrated our incredible team. Their dedication, innovation, and collaboration has driven breakthroughs in #PrecisionOncology and strengthened our mission to improve patient outcomes. Wishing everyone a safe and happy 2026!

010

Foresight Diagnostics @foresight-dx.bsky.social · 07/12/2025

Foresight presents Real-World Data on ultrasensitive #MRD surveillance in B-cell lymphoma today at #ASH2025 (10:45–11:00am ET). The presentation will be posted to the “Resources” section of the website following the session: foresight-dx.com/resources/

010

Foresight Diagnostics @foresight-dx.bsky.social · 05/12/2025

Foresight Diagnostics is now part of Natera Genetics, uniting Natera’s best-in-class precision diagnostics portfolio and commercial and operational infrastructure with our innovative phased-variant ctDNA-MRD technology and lymphoma leadership. Read more: foresight-dx.com/press_releas...

030

Foresight Diagnostics @foresight-dx.bsky.social · 03/12/2025

#ASH25 kicks off in a few days! More than 10 presentations feature #ForesightCLARITY MRD analysis—thanks to our biopharma and academic partners. Don’t miss our oral on CLARITY in #DLBCL surveillance: Sun, Dec 7, 10:45–11am ET. Release: bit.ly/48MWGBP + visit booth #2165!

000

Foresight Diagnostics @foresight-dx.bsky.social · 25/11/2025

The Foresight team is excited to be at #ASH2025! Catch our Oral Presentation on #ForesightCLARITY in #DLBCL surveillance on Sun., Dec. 7 from 10:45–11:00am ET. Stop by booth #2165 to meet our executive team and clinical experts or reach out to BD@foresight-dx.com to connect.

000

Foresight Diagnostics @foresight-dx.bsky.social · 21/11/2025

Join Dr. David Kurtz of Foresight Diagnostics as he reviews Allogene’s phase 2 ALPHA3 trial of cema-cel, an allogeneic CAR T in MRD+ LBCL after frontline therapy, and CLARITY™ MRD data, trial updates, and milestones. Add to calendar: calendarlink.com/event/wpYmu

000

Foresight Diagnostics @foresight-dx.bsky.social · 20/11/2025

Foresight is pushing the boundaries of cancer diagnostics. Co-founders Jake Chabon and Max Diehn and Fierce Biotech’s Chris Hayden discuss how #MRD testing is transforming care and our ultrasensitive approach focused on clinically-actionable decisions for patients: bit.ly/49sQOib

bit.ly

Inside Foresight’s Mission to Redefine Cancer Monitoring

| Discover how Foresight Diagnostics is pushing MRD detection to new limits with its ultrasensitive technology that has the potential to unlock new actionable insights.

000

Foresight Diagnostics @foresight-dx.bsky.social · 19/11/2025

We’re honored to be recognized as one of DeloitteUS’s 2025 Fast 500 companies! As we continue advancing cancer drug development and patient care through innovative diagnostics combining precision genomics and cutting-edge science, we’re inspired to keep pushing boundaries.

000

Foresight Diagnostics @foresight-dx.bsky.social · 17/11/2025

Last night, our team attended the Colorado Avalanche’s Hockey Fights Cancer game with UCHealth - a powerful night of honoring cancer warriors and supporting those affected by cancer. Proceeds benefited the American Cancer Society. #ForesightCLARITY #Oncology

010

Foresight Diagnostics @foresight-dx.bsky.social · 12/11/2025

Foresight is pushing the boundaries of cancer diagnostics. CBO John Truesdell and Fierce Biotech's Chris Hayden discuss how our ultrasensitive #MRD approach can enable clinically-actionable decisions in oncology: youtu.be/OihBGDqEN2s #ctdna #mrd

youtu.be

Foresight Diagnostics executive sees MRD testing as future of cancer care

YouTube video by Fierce Life Sciences

010

Foresight Diagnostics @foresight-dx.bsky.social · 03/11/2025

Will we see you at #ASH25? Foresight will present the first real-world study of ctDNA dynamics in treated #LBCL, showcasing how #ultrasensitive MRD detection can guide personalized treatment. Excited to connect on the next stage of MRD-driven care: bit.ly/47kdmQE

010

Foresight Diagnostics @foresight-dx.bsky.social · 31/10/2025

Spirits are high in the office this week with a little Halloween fun! Our team came together for some friendly competition during our costume contest, sharing laughs and creativity, along with some impressive outfits. Thanks to everyone who joined in!

010

Foresight Diagnostics @foresight-dx.bsky.social · 21/10/2025

Welcome Carrina Cappadona to the team! As our new VP of Patient and Client Experience, Carinna will lead efforts to ensure that patients, clinicians, and providers are supported as we work to develop innovative diagnostic tests to advance cancer drug development and patient care.

010

Foresight Diagnostics @foresight-dx.bsky.social · 17/10/2025

Our Foresight CLARITY™ MRD platform detects the presence of #MRD from circulating tumor DNA (ctDNA) with sensitivity to multiple cancers. Learn about how Foresight CLARITY™ is shaping the next-gen of cancer monitoring: bit.ly/4mpDDRW #UltrasensitiveScience

010

Foresight Diagnostics @foresight-dx.bsky.social · 09/10/2025

Excited to attend #ESMO2025 in Berlin! Foresight team members will be onsite connecting with experts on the latest breakthroughs in #oncology. Curious about our #MRD detection technology, #ForesightCLARITY? Let’s connect! Reach out here: bit.ly/4mZE7yK #BeyondClarity #UltrasensitiveScience

010

Foresight Diagnostics @foresight-dx.bsky.social · 02/10/2025

Curious how ctDNA could reshape care for aggressive cancers like #DLBCL? Hear from co-founder Ash Alizadeh on Blood Cancer Talks on its transformative potential, from advances in detection to breakthrough clinical data. Listen here: bit.ly/4mBkyfr

bit.ly

Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain

Podcast Episode · Blood Cancer Talks · 09/24/2025 · 53m

010

Foresight Diagnostics @foresight-dx.bsky.social · 30/09/2025

Excited to join #FierceBiotechWeek! Our CBO John Truesdell and Allogene Therapeutics CMO Zachary Roberts will discuss how next-gen #MRD is reshaping oncology, driving personalized care, advancing therapies, and informing decisions to improve outcomes. Register here: bit.ly/4nk0C1A

010

Foresight Diagnostics @foresight-dx.bsky.social · 29/09/2025

The Foresight team was proud to support Blood Cancer United at our local #LightTheNight Walk! We sponsored the walkway and cheered on patients, survivors, families, and supporters. It was an inspiring night honoring those impacted by blood cancers and funding life-saving research.

010

Foresight Diagnostics @foresight-dx.bsky.social · 26/09/2025

We had a great time at World CB & CDx Summit this week! A highlight was hosting a lunch & learn with QIAGEN, where we explored opportunities for MRD-driven companion diagnostic development and distribution. Connect with our BD team to learn more about us: bit.ly/4mZE7yK

010

Foresight Diagnostics @foresight-dx.bsky.social · 25/09/2025

We’re thrilled to welcome McKenzie Carlisle, PhD, to the Foresight team! As our new Senior Director of Regulatory Operations and Compliance, she’ll lead regulatory strategy for our IVD pipeline, helping drive innovative diagnostics to advance oncology drug development and patient care.

010

Foresight Diagnostics @foresight-dx.bsky.social · 24/09/2025

On #WorldCancerResearchDay, we reaffirm our goal to give patients actionable data when it matters most. With Foresight CLARITY™, powered by our PhasED-Seq™ technology, we aim to uncover residual disease at key points in treatment. Learn more about us: bit.ly/4pwH3EY

010

Foresight Diagnostics @foresight-dx.bsky.social · 22/09/2025

The Foresight team is excited to join Blood Cancer United's #LightTheNight walk in Denver on Sept. 25 to honor and support those impacted by #bloodcancer. Walk with us, or find an event near you to help raise funds for life-saving research. Sign up here: bit.ly/3IjzEYS

000

Foresight Diagnostics @foresight-dx.bsky.social · 17/09/2025

Looking forward to the Liquid Biopsy Symposium! Michiel Pegtel, PhD and HOVON will present on the value of Foresight CLARITY™ #MRD at end of #DLBCL therapy in a real-world cohort and founder Max Diehn, MD, PhD, will present on advances in liquid biopsies: bit.ly/4mSKNPL

010

Foresight Diagnostics @foresight-dx.bsky.social · 17/09/2025

Excited to be at the upcoming World CB & CDx Summit! Meet us to learn about our technology for detecting #MRD with unmatched sensitivity in cancer types. Ask about our QIAGEN partnership to develop CDx kits for #lymphoma and our global CDx capabilities. More details: world-cdx.com

010

Foresight Diagnostics @foresight-dx.bsky.social · 15/09/2025

Reflecting on a successful #WCLC25! Our team shared our work with University Health Network Toronto on advancing ctDNA analysis in #NSCLC with Foresight CLARITY™ and connected with colleagues, collaborators and others dedicated to improving outcomes in #lungcancer. More details: bit.ly/4gmQh2t

020

Foresight Diagnostics @foresight-dx.bsky.social · 15/09/2025

On #WLAD we recognize challenges patients face post-treatment: ~30% of #DLBCL patients relapse, often taking 1–2 years to confirm with current methods. Foresight CLARITY™ seeks to detect relapse sooner, enabling precise care. Learn more: bit.ly/45yFqgO #BloodCancerMonth

000

Foresight Diagnostics @foresight-dx.bsky.social · 12/09/2025

How is research shaping the future of cancer care? Hear from our CEO & CMO on Mendelspod on Foresight’s origin story, our next-gen #MRD testing with unmatched sensitivity, detecting relapse earlier, and what’s next for cancer care. Listen here: bit.ly/46pUm1A #Oncology

bit.ly

Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz

Catching a cancer relapse before any scan could see it is the ultimate goal for minimal residual disease or MRD testing.

000

Foresight Diagnostics @foresight-dx.bsky.social · 05/09/2025

Company Announcement: Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin’s Lymphoma. The Agreement Closes the Litigation Between the Parties. More information: bit.ly/46fSoki #MRD #Oncology

000

Foresight Diagnostics @foresight-dx.bsky.social · 05/09/2025

Our team is at #WCLC25 this weekend! We’re sharing data with University Health Network Toronto on ctDNA analysis from the ctDNA-Lung-DETECT study in #NSCLC using Foresight CLARITY™, our ultrasensitive next-gen assay, showing high #MRD detection. Details: bit.ly/4g9ynQN

000

Foresight Diagnostics @foresight-dx.bsky.social · 04/09/2025

Don’t miss our webinar on Friday, 9/12 with QIAGEN and Precision Medicine Online! We’ll cover ultra-sensitive #MRD in lymphoma, recent data, and how our collaboration combines Foresight’s ultrasensitive technology with Qiagen’s NGS workflows and diagnostics. Register here: bit.ly/464FJBD

bit.ly

Ultra-Sensitive MRD in Lymphoma: Emerging Clinical Evidence and Expanding Access

Friday, September 12, 2025 at 12:00 PM Eastern Daylight Time.

000

Foresight Diagnostics @foresight-dx.bsky.social · 03/09/2025

Check out this new publication by lead author Paolo Strati in Nature Communications from a Phase 2 trial in patients with advanced #follicularlymphoma using Foresight CLARITY™, achieving ultra-sensitive #MRD detection and outcome prediction. Read here: bit.ly/3I3Vdg4

000

Foresight Diagnostics @foresight-dx.bsky.social · 26/08/2025

Come see us at #WCLC25 in September, where Foresight is presenting in partnership with University Health Network Toronto, featuring ctDNA-MRD analysis utilizing our Foresight CLARITY™ assay in patients with #NSCLC. Session information: bit.ly/3VjxStI To meet with us: bit.ly/4mZE7yK

000

Foresight Diagnostics @foresight-dx.bsky.social · 18/08/2025

Check out our publication in Journal of Clinical Oncology, showing Foresight CLARITY™ delivered greater prognostic accuracy than PET/CT at end of therapy in #LBCL, reinforcing the role of ultrasensitive #MRD testing for remission assessment. Read more: bit.ly/4lz93oi

010

Foresight Diagnostics @foresight-dx.bsky.social · 13/08/2025

Jeff Gregg, VP of Medical Affairs at Foresight, will be at the 17th Annual #NextGenerationDxSummit in D.C.! He’ll discuss how #MRD is moving beyond early detection to help drive clinical decision making, enabled by ultra-sensitive assays like Foresight CLARITY™.

000

Foresight Diagnostics @foresight-dx.bsky.social · 06/08/2025

What a great day! Thanks to all our team members who joined us for food, fun and giving back. Shout out to our team members for taking the plunge in the dunk tank to raise funds for The Leukemia & Lymphoma Society Denver! #ForesightCLARITY #PrecisionOncology #MRDdetection #Biotechnology #startup

000

Foresight Diagnostics @foresight-dx.bsky.social · 18/07/2025

Check out an interview our CMO David Kurtz, MD, PhD, did with The Pathologist about how #MRD testing is advancing personalized lymphoma care, and how real-world data supports Foresight CLARITY™ for use at end of #DLBCL treatment. Full article: bit.ly/3IyWKL4

bit.ly

Seeing What PET Misses

The inclusion of molecular MRD testing in NCCN guidelines marks a turning point for personalized lymphoma diagnostics

000

Foresight Diagnostics @foresight-dx.bsky.social · 16/07/2025

This #ASCO2025 Insights video highlights @columbiauniversity.bsky.social’s innovative SHORTEN-ctDNA trial using Foresight CLARITY™ MRD to help personalize #chemotherapy treatment and avoid unnecessary toxicity. Watch here: bit.ly/408uxR9 Read the data: bit.ly/43LAvbs

bit.ly

ASCO® 2025 Insights: Sequencing-Guided Chemo Optimization Using ctDNA in Newly Diagnosed DLBCL - The SHORTEN-ctDNA Trial

A video from Hua-Jay Cherng (as part of 2025 ASCO® Annual Meeting Insights Hub), posted on Jun 5, 2025.

000

Foresight Diagnostics @foresight-dx.bsky.social · 10/07/2025

Dr. Jeremy Abramson (Mass General/Harvard) spotlighted Foresight CLARITY #MRD detection in a prospective, real-world cohort presented at #ASCO2025. At Foresight, we’re proud to back tools driving smarter interventions and personalized treatment. Watch here: bit.ly/4kb7o7D

bit.ly

Dr Abramson on ASCO 2025 DLBCL Updates: What's New?

Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual Meeting.

000

Foresight Diagnostics @foresight-dx.bsky.social · 04/07/2025

This Independence Day, we celebrate freedom, resilience, and the pursuit of better health. We’re committed to advancing #cancer detection through #MRD testing — because independence in health matters. #IndependenceDay #FourthOfJuly #PrecisionMedicine #Oncology #MRD

010

Foresight Diagnostics @foresight-dx.bsky.social · 25/06/2025

Our VP of Medical Affairs will participate in a panel titled “Defining Endpoints & MRD Strategies to Advance Precision Oncology Trials” at the Liquid Biopsy for Precision Oncology Summit in Boston! #MRD #ctDNA #CancerDiagnostics #PrecisionMedicine #LiquidBiopsy #ClinicalTrials

000

Foresight Diagnostics @foresight-dx.bsky.social · 25/06/2025

On #NationalCancerSurvivorMonth, we honor the strength, resilience and courage of all cancer #survivors and their families. We look forward to helping clinicians detect #relapse more quickly so patients can get the treatment they need to beat cancer and #survive.

000

Foresight Diagnostics @foresight-dx.bsky.social · 11/06/2025

Our team is looking forward to meeting with partners at #BIO2025, June 16-19 in Boston! Interested in learning more about Foresight CLARITY™ MRD detection for lymphoma and solid tumors? Contact us to arrange a meeting: lnkd.in/eXurmSst #MRD #ctDNA #PrecisionMedicine #Oncology

010

Foresight Diagnostics @foresight-dx.bsky.social · 10/06/2025

We are pleased to share that we will present at #EHA2025 and #18ICML an encore of the prognostic value of Foresight CLARITYTM MRD detection in #DLBCL. Additionally, we will present a poster on behalf of our partner, @KitePharma. Read more: bit.ly/4n0f8MI

000

Foresight Diagnostics @foresight-dx.bsky.social · 02/06/2025

We are happy to announce that we’ve begun a strategic partnership with QIAGEN to advance development of companion diagnostic kits for #Lymphoma. More information about the partnership here: bit.ly/3FCupSP #ctDNA #MRD #cancer

000

Foresight Diagnostics @foresight-dx.bsky.social · 22/05/2025

Don’t forget to attend our oral and poster presentations of new data in newly diagnosed #DLBCL at #ASCO25. Stop by our booth, IH #3, to see how we are powering precision for improved clinical trials. Read more: bit.ly/4k6grrg

000

Foresight Diagnostics @foresight-dx.bsky.social · 20/05/2025

For #CTD25 and #NCRM25 we want to highlight our commitment to improving outcomes for patients and bring awareness to MRD-driven clinical trials! More about our current partnerships here: t.ly/DJmYh

000

Foresight Diagnostics @foresight-dx.bsky.social · 12/05/2025

We are excited to share that our CEO, Jake Chabon, will attend the Jefferies Global Healthcare Conference on June 3-4, 2025, in New York City. He will be available for 1x1 meetings on both days. To schedule a meeting: bit.ly/4jIyl3j #MRD #ctDNA #PrecisionMedicine

010

Foresight Diagnostics @foresight-dx.bsky.social · 01/05/2025

We are pleased to have the opportunity to share both an oral and poster presentation of new data in newly diagnosed #DLBCL at #ASCO25. Stop by our booth, IH #3, to see how we are powering precision for improved clinical trials. Read more: bit.ly/4jBgdII

010

Foresight Diagnostics @foresight-dx.bsky.social · 10/04/2025

We are looking forward to attending #AACR25. Interested in learning more about our Foresight CLARITY™ ultra-sensitive #MRD for lymphoma and solid tumors? Contact us to arrange a meeting: lnkd.in/etNExaqs #ctDNA #PrecisionMedicine #Oncology #CancerResearch #Lymphoma

010